La Grande-3 Airport

Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, August 4, 2021
James Bay Project, La Grande-3 Airport, Oncology, Patti, Iran

This is an exciting time in our Companys history as we plan for a steady stream of milestones in the second half of 2021, commented Filippo Petti, Chief Executive Officer of Celyad Oncology.

Key Points: 
  • This is an exciting time in our Companys history as we plan for a steady stream of milestones in the second half of 2021, commented Filippo Petti, Chief Executive Officer of Celyad Oncology.
  • Research & Development Day held on July 20, 2021, during which the management team provided:
    Updates on the allogeneic CAR T clinical candidates CYAD-211 and CYAD-101.
  • Report additional data from the dose-escalation Phase 1 CYCLE-1 trial evaluating CYAD-02 in r/r AML and MDS by year-end 2021.
  • Key financial figures for the first half of 2021, compared with the first half of 2020 and full year 2020, are summarized below:

Celyad Oncology Announces Third Quarter 2020 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 10, 2020
Food and Drug Administration, United States Public Health Service, La Grande-3 Airport

As of September 30, 2020, the Company ended the quarter with a treasury position of 20.0 million ($23.4 million).

Key Points: 
  • As of September 30, 2020, the Company ended the quarter with a treasury position of 20.0 million ($23.4 million).
  • Net cash burn during the third quarter of 2020 amounted to 6.7 million ($7.8 million), in line with expectations.
  • In July 2020, Celyad Oncology announced FDA clearance of its IND application for CYAD-211 and subsequently received CTA approval for CYAD-211 by the FAMHP.
  • Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncologys pipelines and financial condition, results of operation and business outlook.

Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights

Retrieved on: 
Thursday, August 6, 2020
RNA, RNA interference, Short hairpin RNA, La Grande-3 Airport, Lluís Companys, Government of Spain, Spanish politicians, Government

Enrollment in the expansion cohort of the study is expected to begin during the fourth quarter of 2020.

Key Points: 
  • Enrollment in the expansion cohort of the study is expected to begin during the fourth quarter of 2020.
  • CYAD-211 is the lead program from the Companys CYAD-200 series of proprietary non-gene edited allogeneic short hairpin (shRNA)-based CAR T candidates.
  • By the end of the second quarter, recruitment in the CYAD-01 THINK and DEPLETHINK trials had recovered.
  • Key financial figures for half year 2020, compared with half year 2019, are summarized below:

Celyad Announces June 2020 Conference Schedule

Retrieved on: 
Tuesday, May 26, 2020
James Bay Project, La Grande-3 Airport

In particular it should be noted that the data summarized above are preliminary in nature.

Key Points: 
  • In particular it should be noted that the data summarized above are preliminary in nature.
  • There is limited data concerning safety and clinical activity following treatment with the CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series product candidates.
  • These results may not be repeated or observed in ongoing or future studies involving the CYAD-01, CYAD-02, CYAD-100 Series and CYAD-200 Series drug product candidates.
  • Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Celyad Announces Board of Directors Evolution with New Appointment

Retrieved on: 
Friday, November 29, 2019
Health, Drug discovery, Pharmaceutical industry, Pharmacology, Clinical research, Design of experiments, Clinical trial, Pre-clinical development, La Grande-3 Airport

In particular it should be noted that the data summarized above are preliminary in nature.

Key Points: 
  • In particular it should be noted that the data summarized above are preliminary in nature.
  • There is limited data concerning safety and clinical activity following treatment with the CYAD-01, CYAD-101 and CYAD-02 drug product candidates.
  • Prior clinical and preclinical results may not be repeated or observed in ongoing or future clinical studies involving the CYAD-01 and CYAD-101 drug product candidates.
  • Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.